Wegovy vs Ozempic: same molecule, different jobs

Wegovy vs Ozempic at a glance

Both are Schedule 4 medicines: each requires a doctor's assessment and authorisation, and only licensed pharmacies may dispense them. Everything else in the Wegovy vs Ozempic comparison flows from those two rows near the top: the dose range and the registered job.

Are Wegovy and Ozempic the same thing?

No. They share the same active ingredient, semaglutide, but they are separate registered medicines. Wegovy delivers semaglutide at doses up to 2.4 mg weekly and is registered for chronic weight management. Ozempic delivers up to 1 mg weekly in South Africa and is registered for type 2 diabetes. Same molecule, two different jobs.

The history explains the split. Novo Nordisk developed semaglutide for type 2 diabetes, and it was first approved as Ozempic in 2017. The diabetes trials kept recording the same secondary finding: participants lost meaningful weight. Dedicated obesity trials followed at a higher dose, and in 2021 that version was approved for weight management under the name Wegovy.

The molecule itself mimics GLP-1, a gut hormone released after eating. It curbs appetite, slows stomach emptying and steadies blood sugar, which is why one compound can hold two registrations. Our guide to what semaglutide is and how it works unpacks the mechanism properly.

What is each registered for in South Africa?

SAHPRA registers Ozempic for type 2 diabetes, including reducing the risk of major cardiovascular events in adults with diabetes and heart disease. Wegovy is registered for chronic weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition, alongside diet and activity changes.

Wegovy launched in South Africa in August 2025 in five pen strengths, the first semaglutide product registered here specifically for weight management. The launch story, stock picture and dosing detail sit in is Wegovy available in South Africa.

Ozempic is sold locally in two pen presentations: one delivering 0.25 mg and 0.5 mg doses, and one delivering 1 mg. The 2 mg pen sold in some other countries has not been part of the routine local range, which caps the registered ladder at 1 mg here.

South African doctors may, at their clinical discretion, use a registered medicine outside its registered indication. That happened widely with Ozempic before Wegovy arrived, and it remains off-label: a clinical decision a doctor takes responsibility for after a full assessment, not a product a patient picks off a shelf.

How do the dose ladders compare?

Both ladders start at 0.25 mg weekly and step up roughly every four weeks. Ozempic's registered ladder in South Africa stops at 1 mg. Wegovy's continues through 1.7 mg to a 2.4 mg maintenance dose, reached after about 16 weeks. One pen of either product holds four weekly doses, close to a month each.

The starting doses are not treatment doses; they exist to let the stomach adjust before the working dose arrives. Nor is the top of either ladder a target. Some people hold Wegovy at 1.7 mg, and many people with diabetes stay at 0.5 mg of Ozempic, because the right dose is the one that balances results against side effects for that person.

What do the trials show about weight loss?

The two were tested in different programmes with different goals. Wegovy's STEP 1 trial measured weight: adults without diabetes lost an average of 14.9% of body weight over 68 weeks. Ozempic's SUSTAIN programme measured blood sugar control in type 2 diabetes, with weight loss a secondary outcome of roughly 4.6 to 6.5 kg. Individual results vary.

STEP 1 followed 1,961 adults with obesity, or overweight plus a weight-related condition, on 2.4 mg weekly against placebo, with diet and activity support in both groups. The semaglutide group averaged 14.9% weight loss against 2.4% on placebo, about 86% lost at least 5% of body weight, and roughly one in three lost 20% or more. Individual results vary.

SUSTAIN 7, a diabetes trial comparing semaglutide with another weekly medicine, recorded average weight reductions of about 4.6 kg on the 0.5 mg dose and 6.5 kg on 1 mg over 40 weeks, with blood sugar the primary measure. Those are the doses Ozempic delivers locally.

Registration follows evidence: the weight-management registration stands on the STEP programme, and the diabetes registration stands on SUSTAIN.

Has any trial compared the two doses directly?

Yes, one. STEP 2 randomised 1,210 adults with type 2 diabetes and a BMI of 27 or more to semaglutide 2.4 mg, semaglutide 1 mg or placebo for 68 weeks. Average weight loss was 9.6% on 2.4 mg, 7% on 1 mg and 3.4% on placebo. Individual results vary.

Three readings matter. The higher dose produced more weight loss, which is why the weight-management registration sits at 2.4 mg. The 1 mg arm still lost a clinically meaningful amount, so the gap between the doses is real but not enormous. And everyone in STEP 2 had type 2 diabetes, a group that loses less on average than people without it, which is why both figures sit below STEP 1's 14.9%.

STEP 2 was a dose comparison, not a trial of Ozempic against Wegovy as products, and no trial average predicts an individual. It is simply the cleanest evidence available on what the dose difference is worth.

Why not simply use Ozempic for weight loss?

Because registration, dose and supply all point the other way. Ozempic is registered for type 2 diabetes, its local pens stop at 1 mg, and weight-management use is off-label. Since Wegovy launched in August 2025, a doctor building a weight plan around semaglutide has a registered product made for that job.

The dose ceiling is the clinical half of the answer: the weight-management evidence was built at 2.4 mg, a dose no Ozempic pen sold here delivers. The supply half is practical. During the shortage years, weight-loss demand for Ozempic made it harder for people with type 2 diabetes to fill their monthly supply.

Off-label treatment remains lawful where a doctor judges it appropriate, and situations exist where it still makes sense. That judgement belongs in a consultation, weighed against the registered alternative, not in a comparison article.

How do the published prices compare?

Business Day reported mid-2026 single exit prices of about R1,438 for the Ozempic pen covering the 0.25 mg and 0.5 mg doses and about R2,876 for the 1 mg pen. Wegovy's reported figures run from about R1,873 per month at the starting dose to R3,746 at the 2.4 mg maintenance dose. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

Wegovy's numbers are the product of movement. Reuters reported that Novo Nordisk cut its South African price twice inside eight months, in December 2025 and again in March 2026, with the lowest dose falling from R3,090 to R1,873 and the highest dose dropping 27% to about R3,746.

Under the Single Exit Price system, every pharmacy sells the same pen at the same regulated medicine price, only a capped dispensing fee differs between chains, and annual increases are capped nationally. Your dose is therefore the main driver of monthly cost, and each pen of either product covers about a month at its labelled strength.

Per-strength breakdowns sit in how much Ozempic costs in South Africa and how the Wegovy price is set. A bare Wegovy vs Ozempic price comparison misleads, because the two headline numbers belong to different indications and different maintenance doses.

What changed in the semaglutide market in 2026?

Competition arrived. Novo Nordisk's South African semaglutide patent expired in March 2026. SAHPRA approved the country's first generic semaglutide, from Sun Pharma, in July 2026, and Novo Nordisk itself launched Extensior, an authorised copy of Ozempic, in late July 2026. Every one of these products is registered for type 2 diabetes.

More are queued: Medical Brief reported 12 further generic semaglutide applications under SAHPRA review in July 2026. Business Day reported Extensior carrying the same semaglutide in the same two pen presentations as Ozempic.

None of this touches the weight-management side yet. No generic or copy semaglutide is registered for weight management in South Africa, so Wegovy remains the only registered semaglutide option for that indication. Anything marketed as generic Wegovy, compounded semaglutide or a slimming vial sits outside the register, and SAHPRA has warned repeatedly that such products have unverified contents. New entrants will keep pressure on published prices; they do not change how the medicines may be used.

Do Wegovy and Ozempic have the same side effects?

Yes, broadly, because the molecule is the same. The common effects are nausea, vomiting, diarrhoea, constipation and stomach discomfort, concentrated in the early weeks and around dose increases. Wegovy's ladder climbs higher, which is exactly why its escalation runs slowly. Most symptoms settle as the body adjusts.

The exclusions are shared too. Neither product should be used in pregnancy or while breastfeeding, or by anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and a history of pancreatitis calls for a careful medical decision. Severe, persistent stomach pain on either medicine can signal pancreatitis: seek medical care immediately.

One difference follows the indication rather than the molecule. People using Ozempic for diabetes alongside insulin or sulfonylureas can experience low blood sugar, so a doctor watches those combinations closely. Day to day, smaller meals, slower eating and steady fluids carry most people through dose steps, and a doctor can hold a step longer where symptoms drag.

Can you switch between Ozempic and Wegovy?

Yes, with a doctor managing the change. The molecule is identical, so a switch is mostly about mapping your current dose onto the other product's ladder, but the registrations and pen strengths differ, so it is a planned clinical change rather than a swap at the pharmacy counter. Never use both at once.

The common scenario runs in one direction: someone whose weight was being treated off-label on Ozempic moving across to the registered option now that it exists. The doctor reviews the response so far, picks a sensible entry strength on the Wegovy ladder, and follows up while the change beds in.

Do not adjust doses yourself along the way. The pen strengths of the two products do not map one to one, and a doubled or skipped week of semaglutide adds side effects without adding benefit. Timing, entry dose and follow-up are the doctor's to plan.

Does medical aid treat Wegovy and Ozempic differently?

Often, yes, because scheme rules follow the registered indication. Several schemes fund semaglutide for type 2 diabetes under chronic benefits, which is where Ozempic sits. Obesity is not a Prescribed Minimum Benefit condition, so most schemes exclude weight-loss treatment, and Wegovy is usually paid for out of pocket.

Scheme rules shift, and some plans allow payment from medical savings accounts even where the benefit itself is excluded, so ask your scheme for its criteria and exclusion list in writing before assuming either answer. How cover, exclusions and motivation letters work across schemes is set out in our medical aid guide.

How does a doctor choose between them?

By the job the medicine must do. For type 2 diabetes, Ozempic is one of the registered choices, and scheme funding often follows. For weight management, the registered semaglutide option is Wegovy, and the working comparison is usually Wegovy against tirzepatide, the other molecule registered for weight management here.

The assessment does the deciding: medical history, current medicines, the exclusions above, budget, and whether a pharmacy can stock a chosen strength reliably month after month. Trial averages inform that conversation without finishing it. Individual results vary, and the right option is decided by a doctor on assessment.

For the comparison across molecules rather than within one, see semaglutide vs tirzepatide.

Frequently asked questions